The expression of DLGAP5 has been found to be upregulated in several cancers, such as endometrial cancer (Chen et al., 2023[7]), ovarian cancer (Zhang et al., 2021[47]), bladder cancer (Rao et al., 2022[32]), hepatocellular cancer (Liao et al., 2013[23]), pancreatic cancer (Ke et al., 2020[19]), and lung cancer (Tagal et al., 2017[37]). Here, DLGAP5 is linked to ovarian carcinoma.